NUMAB
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.
NUMAB
Industry:
Biopharma Biotechnology Health Care Health Diagnostics Life Science Medical Therapeutics
Founded:
2011-01-01
Address:
Wadenswil, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.numab.com
Total Employee:
11+
Status:
Active
Contact:
41445330471
Email Addresses:
[email protected]
Total Funding:
122 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ARNA Genomics
ARNA Genomics is a biotechnology company that specializes in developing fluid biopsy technology.
Beta Bugs Limited
Beta Bugs is an insect genetics company that develops and distributes high-performance Black Soldier Fly breeds to insect farmers.
Biomnigene
Biomnigene is a biotechnology agency that offers DNA/RNA extraction to microbiome analysis and research services.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Genomics
Genomics plc aiming to lead the genomic transformation of healthcare.
Imago BioSciences
Imago is a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs).
Libre Foods
Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet and animals.
Oxitec
Oxitec develops an environment-friendly technology for the control of significant insect pests to prevent diseases and agricultural damage.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Numab
HBM Partners
HBM Partners investment in Series C - Numab
BlackRock
BlackRock investment in Series C - Numab
Forbion Capital Partners
Forbion Capital Partners investment in Series C - Numab
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Numab
RTW Investments LLC
RTW Investments LLC investment in Series C - Numab
BVF Partners
BVF Partners investment in Series C - Numab
Novo Holdings
Novo Holdings investment in Series C - Numab
Octagon Capital Advisors
Octagon Capital Advisors investment in Series C - Numab
3sbio
3sbio investment in Series B - Numab
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-12 | 3sbio | Numab investment in Post-IPO Equity - 3sbio | 15 M CHF |
Official Site Inspections
http://www.numab.com Semrush global rank: 8.83 M Semrush visits lastest month: 245
- Host name: 212.243.197.113
- IP address: 212.243.197.113
- Location: Onex Switzerland
- Latitude: 46.1877
- Longitude: 6.0981
- Timezone: Europe/Zurich
- Postal: 1213
More informations about "Numab"
Numab Therapeutics AG
Using a novel, rational process, our discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first …See details»
Numab Therapeutics AG
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer Read moreSee details»
About us - Numab Therapeutics AG
Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of new and important …See details»
Numab Therapeutics AG – Swiss Biotech
We specialize in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we …See details»
Numab - Crunchbase Company Profile & Funding
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases. Numab may be growing as evidenced by a significant acquisition deal where J&J purchased a Numab antibody for $1.25 …See details»
Numab - Org Chart, Teams, Culture & Jobs - The Org
View Numab's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
ONO Enters into an Option and Collaboration Agreement with …
Feb 14, 2024 · Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery …See details»
Organization | Numab Therapeutics AG
Organization Overview. First Clinical Trial. 2020 NCT04442126. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Numab Therapeutics AG Active Ingredients. …See details»
BI & Numab Therapeutics Enter into Collaboration | BI US
Boehringer Ingelheim and Numab Therapeutics (Numab) announced that they have entered into a research collaboration and worldwide licensing agreement.See details»
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific ...
NEW BRUNSWICK, NJ (May 28, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage …See details»
Numab Therapeutics and Ono Pharmaceutical Enter ... - Business …
Mar 31, 2022 · Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy …See details»
Partnering - Numab Therapeutics AG
Numab offers its cutting-edge discovery engine to partners looking to develop innovative antibody-based therapeutics with multiple specificities, tailored half-lives, unrivaled potency, and ready …See details»
Numab Company Profile 2024: Valuation, Funding & Investors
Operator of a biopharmaceutical company intended to develop multispecific antibody-based immunotherapies.See details»
Numab Therapeutics: First patient dosed in clinical study to …
Aug 24, 2020 · Numab Therapeutics AG announced today the first patient has been dosed in its proprietary ND021 program, a next-generation tri-specific immuno-oncology approach …See details»
Numab Therapeutics and Ono Pharmaceutical Announce an …
HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, …See details»
ONO Enters into a Development and License Agreement with …
Mar 31, 2022 · Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO, Gyo Sagara; “Ono”) today announced that it has exercised its option to enter into a development and …See details»
Numab Therapeutics AG | Investors
Advancing a proprietary pipeline of next generation immunology and immuno-oncology drugs. Developing the best MATCH for patients through plug & play assembly of novel multispecific …See details»
Numab Therapeutics Completes Oversubscribed CHF 100 Million …
May 20, 2021 · Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer …See details»
Numab raises $111M to challenge Genmab, BioNTech for …
May 20, 2021 · Numab Therapeutics has raised CHF 100 million ($111 million) to expand clinical development of its lead PD-L1x4-1BB drug candidate into multiple cancer indications. Novo …See details»
Numab Company Profile - Office Locations, Competitors, Revenue …
Numab Therapeutics is an oncology-focused biopharmaceutical company. It develops multispecific antibody-based immunotherapies. The company provides a platform that reduces …See details»